Treatment benefit of upfront autologous stem cell transplantation for newly diagnosed multiple myeloma: a systematic review and meta-analysis
Journal
BMC cancer
Journal Volume
23
Journal Issue
1
Date Issued
2023-05-16
Author(s)
Abstract
Upfront high-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) remains a profitable strategy for newly diagnosed multiple myeloma (MM) patients in the context of novel agents. However, current knowledge demonstrates a discrepancy between progression-free survival (PFS) and overall survival (OS) benefit with HDT/ASCT.
Subjects
Autologous stem-cell transplantation; Meta-analysis; Multiple myeloma; Survival; Systematic review
SDGs
Type
journal article